Keenova's XIAFLEX Shows Promise in Phase 3 Trial for Plantar Fibromatosis
Event summary
- Keenova Therapeutics reported positive Phase 3 trial results for XIAFLEX in treating plantar fibromatosis, meeting primary and key secondary endpoints.
- The trial demonstrated statistically significant pain reduction and functional improvements compared to placebo.
- No serious adverse events were reported, with most side effects rated mild to moderate.
- Keenova plans to submit an FDA application for this indication in Q4 2026, targeting a 2028 launch.
The big picture
Keenova's success in repurposing XIAFLEX for plantar fibromatosis highlights its strategy of expanding its portfolio into rare disease areas with unmet needs. The positive trial results position the company to potentially capture a significant share of a market currently dominated by non-pharmacological interventions. This move aligns with broader industry trends toward targeted therapies for niche conditions, where regulatory pathways can be more streamlined compared to broader indications.
What we're watching
- Regulatory Timing
- Whether the FDA submission in Q4 2026 will proceed smoothly and meet expectations for a 2028 launch.
- Market Potential
- The size of the addressable market, with Keenova projecting 300,000 patients seeking treatment by 2028.
- Competitive Dynamics
- How this expansion positions XIAFLEX against existing treatments for plantar fibromatosis, currently limited to symptom management or surgery.